U.S. court ruling favors Cubist in patent case versus Hospira
(Reuters) - A federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc <CBST.O> on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc <HSP.N>. Full story

